🎨 Segmental vs Non-Segmental Vitiligo Simulator

Segmental Vitiligo — Unilateral Dermatomal Distribution

Placeholder: segmental vitiligo follows a single-sided skin segment.

• 1: Body sides affected (Placeholder unilateral)
• <20: Typical onset age (Placeholder early onset)
• High: Dermatome match (Placeholder nerve pattern)
• ~10%: Prevalence share (Placeholder of all vitiligo)

Unilateral dermatomal distribution

Placeholder: patch boundary tracks a cutaneous dermatome closely.

Segmental Vitiligo — Early Onset and Rapid Stabilization

Placeholder: segmental disease tends to stop spreading within a year or two.

• 6-24mo: Stabilization time (Placeholder typical window)
• Low: Relapse rate (Placeholder after stabilizing)
• Common: Hair involvement (Placeholder poliosis)
• High: Response to graft (Placeholder surgical success)

Rapid stabilization course

Placeholder: growth halts early, leaving a fixed unilateral patch.

Non-Segmental Vitiligo — Bilateral Symmetric Distribution

Placeholder: non-segmental vitiligo appears as mirrored bilateral patches.

• 2: Body sides affected (Placeholder bilateral)
• ~90%: Prevalence share (Placeholder of all vitiligo)
• High: Symmetry (Placeholder mirrored patches)
• Strong: Autoimmune link (Placeholder comorbidity)

Bilateral symmetric distribution

Placeholder: patches emerge on corresponding sites on both sides.

Non-Segmental Vitiligo — Progressive Lifelong Course

Placeholder: non-segmental disease relapses and spreads over decades.

• Lifelong: Course length (Placeholder chronic relapsing)
• Gradual: Spread pattern (Placeholder new patches over years)
• Frequent: Koebner sign (Placeholder trauma-triggered)
• Rare: Spontaneous repigment (Placeholder limited recovery)

Progressive lifelong spread

Placeholder: new symmetric patches accumulate slowly with age.

Treatment Strategy Differs By Vitiligo Type

Placeholder: stable segmental disease favors surgery, active non-segmental favors medical therapy.

• Grafting: Segmental first-line (Placeholder surgical repigmentation)
• Phototherapy: Non-segmental first-line (Placeholder NB-UVB)
• Non-seg only: Systemic therapy (Placeholder immunomodulation)
• Stability: Graft success driver (Placeholder disease quiescence)

Type-directed treatment choice

Placeholder: stability and pattern guide surgical vs medical therapy.

Placeholder: matching treatment to vitiligo type improves outcomes.